Last reviewed · How we verify

NCT02756897

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

Active, enrolled Phase 2 Last updated 19 February 2026
What this trial tests

Phase 2 trial testing Ibrutinib in Chronic Lymphocytic Leukemia in 234 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
7 July 2016
Primary endpoint
1 July 2027
1 July 2027

Quick facts

Lead sponsorM.D. Anderson Cancer Center
PhasePhase 2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment234
Start date7 July 2016
Primary completion1 July 2027
Estimated completion1 July 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Chronic Lymphocytic Leukemia or Recurrent Chronic Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well venetoclax and ibrutinib work in treating patients with chronic or small lymphocytic leukemia. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and ibrutinib may help control chronic or small lymphocytic leukemia.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    Jain N, Keating M, Thompson P, Ferrajoli A, et al · · 2019 · cited 376× · PMID 31141631 · DOI 10.1056/nejmoa1900574
  2. Pathways and mechanisms of venetoclax resistance.
    Bose P, Gandhi V, Konopleva M. · · 2017 · cited 223× · PMID 28140720 · DOI 10.1080/10428194.2017.1283032
  3. Evaluation of synergism in drug combinations and reference models for future orientations in oncology.
    Duarte D, Vale N. · · 2022 · cited 198× · PMID 35620200 · DOI 10.1016/j.crphar.2022.100110
  4. BCL-2 as therapeutic target for hematological malignancies.
    Perini GF, Ribeiro GN, Pinto Neto JV, Campos LT, et al · · 2018 · cited 153× · PMID 29747654 · DOI 10.1186/s13045-018-0608-2
  5. Small molecule inhibitors targeting the cancers.
    Liu GH, Chen T, Zhang X, Ma XL, et al · · 2022 · cited 127× · PMID 36254250 · DOI 10.1002/mco2.181
  6. Targeting the Bcl-2 Family in B Cell Lymphoma.
    Adams CM, Clark-Garvey S, Porcu P, Eischen CM. · · 2018 · cited 112× · PMID 30671383 · DOI 10.3389/fonc.2018.00636
  7. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
    Roberts AW, Huang D. · · 2017 · cited 104× · PMID 27806433 · DOI 10.1002/cpt.553
  8. Microenvironmental agonists generate <i>de novo</i> phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.
    Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, et al · · 2017 · cited 94× · PMID 29034364 · DOI 10.1182/bloodadvances.2016004176

Verify or expand the search:

Other trials of Ibrutinib

Trials testing the same drug.

Other recruiting trials for Chronic Lymphocytic Leukemia

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02756897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing